AcelRx Pharmaceuticals: On May 30, 2019, The Companyentered Into A Loan And Security Agreement, Or The Loan Agreement, With Oxford Finance Llc, Or Oxford. Under The Loan Agreement, Oxford Made A Term Loan To The Company In An Aggregate Principal Amount Of $25.0 Million, Or The Loan, Which Was Funded On May 30, 2019. Payments On The Loan Were Interestonly Until July 1, 2020, Followed By Equal Principal Payments And Monthly Accrued Interest Payments Through The Scheduled Maturity Date Of June 1, 2023. The Outstanding Balance Due Under The Loan Agreement Was $5.4 Million At December 31, 2022. The Loan Agreement Is Filed As Exhibit 10.1 To Our Current Report On Form 8k As Filed With The Sec On June 3, 2019, As Amended On May 5, 2021, With Such First Amendment Filed As Exhibit 10.4 To Our Quarterly Report On Form 10q As Filed With The Sec On November 15, 2021, And As Further Amended On November 14, 2021, With Such Second Amendment Filed As Exhibit 10.31 To Our Annual Report On Form 10k As Filed With The Sec On March 10, 2022, Completion Of Acquisition Or Disposition Of Assets, Regulation Fd Disclosure, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Talphera Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***